本文選題：甲磺酸阿帕替尼　切入點(diǎn)：非小細(xì)胞肺癌　出處：《中國(guó)腫瘤臨床》2017年02期

【摘要】：正患者女性,57歲,無(wú)吸煙史。因咳痰伴痰中帶血1個(gè)月于2012年3月就診陸軍總醫(yī)院,PET-CT檢查提示:右肺癌,肺門(mén)、縱隔多發(fā)淋巴結(jié)轉(zhuǎn)移,L2骨轉(zhuǎn)移。免疫組織化學(xué)檢測(cè):肺來(lái)源可能性大。心包積液檢測(cè)示:查見(jiàn)鱗癌(圖1),EGFR基因突變陰性。診斷為:1)右肺鱗癌Ⅳ期(pT4N3M1),肺門(mén)、縱隔多發(fā)淋巴結(jié)轉(zhuǎn)移癌,骨轉(zhuǎn)移癌,心包積液。2)高血壓Ⅲ級(jí)高危�；颊呔芙^放、化療,服用靶向藥物治療。遂于2012年3月開(kāi)始口服靶向藥物
[Abstract]:The female patient, 57 years old, had no history of smoking. PET-CT examination at Army General Hospital in March 2012, due to expectoration and sputum with blood in one month, showed that: right lung cancer, hilar lung, Mediastinal multiple lymph node metastasis with L2 bone metastases. Immunohistochemical examination: lung origin is very likely. Pericardial effusion detection shows that squamous cell carcinoma (fig. 1) has negative EGFR gene mutation and is diagnosed as: right lung squamous cell carcinoma stage 鈪，

本文編號(hào)：1666274